Page last updated: 2024-09-05

olpadronic acid and Disease Exacerbation

olpadronic acid has been researched along with Disease Exacerbation in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hillegonds, DJ; Hoffman, RM; Yang, M	1

Other Studies

1 other study(ies) available for olpadronic acid and Disease Exacerbation

Article	Year
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-15, Volume: 12, Issue:8 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Disease Progression; Glycoproteins; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays	2006

Article

Year

The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-15, Volume: 12, Issue:8

Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Disease Progression; Glycoproteins; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays

2006